Number of SEER-MHOS Respondents (Age 65+) by First Cancer Site, 1998-2017
| First Cancer (#) | Number of linked Patients with One or More survey (Group A) |
More than one survey* (Subset of Group A) |
Survey before Cancer Diagnosis (Group B) |
Survey both before and after Cancer Diagnosis** (Subset of Group B) |
Survey after Cancer Diagnosis (Group C) |
||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | ||
| Prostate (28010) | 35,128 | 16,221 | (46.18) | 10,215 | (29.08) | 2,380 | (6.78) | 27,289 | (77.68) |
| Breast (26000) | 31,407 | 15,145 | (48.22) | 9,063 | (28.86) | 1,955 | (6.22) | 24,295 | (77.36) |
| Colorectal (21041-21052) | 18,993 | 8,661 | (45.60) | 7,568 | (39.85) | 1,211 | (6.38) | 12,634 | (66.52) |
| Lung and bronchus (22030) | 14,880 | 5,836 | (39.22) | 11,400 | (76.61) | 854 | (5.74) | 4,329 | (29.09) |
| Ovary (27040) | 1,879 | 837 | (44.54) | 945 | (50.29) | 100 | (5.32) | 1,034 | (55.03) |
| Uterus(27020, 27030) | 5,675 | 2,709 | (47.74) | 1,431 | (25.22) | 287 | (5.06) | 4,531 | (79.84) |
| Cervix (27010) | 2,500 | 1,108 | (44.32) | 189 | (7.56) | 18 | (0.72) | 2,329 | (93.16) |
| Bladder (29010) | 8,733 | 3,953 | (45.27) | 3,895 | (44.60) | 654 | (7.49) | 5,492 | (62.89) |
| Melanomas - skin (25010) | 9,456 | 4,682 | (49.51) | 3,702 | (39.15) | 679 | (7.18) | 6,417 | (67.86) |
| Head and Neck (20010-20100, 22010, 22020) | 4,365 | 1,904 | (43.62) | 1,743 | (39.93) | 254 | (5.82) | 2,876 | (65.89) |
| Kidney and Renal pelvis (29020) | 3,898 | 1,765 | (45.28) | 1,842 | (47.26) | 307 | (7.88) | 2,363 | (60.62) |
| Non-Hodgkin's lymphomas - nodal and extranodal (33041,33042) | 5,479 | 2,449 | (44.70) | 2,877 | (52.51) | 382 | (6.97) | 2,983 | (54.44) |
| Stomach (21020) | 2,040 | 805 | (39.46) | 1,375 | (67.40) | 111 | (5.44) | 776 | (38.04) |
| Pancreas (21100) | 2,698 | 1,033 | (38.29) | 2,446 | (90.66) | 92 | (3.41) | 344 | (12.75) |
* At least one survey must be two years after first survey.
** Number of individuals with a survey before their first cancer diagnosis and also a survey after their first cancer diagnosis.
Note: The denominator for the percentages that appear in columns 3 through 6 is the Number of linked patients with one or more survey by cancer site (column 2).
The groups in columns 4 through 6 are not mutually exclusive, therefore, the percentages do not sum to 100.